Shilpa Medicare gains 5% on launch of generic drug for kidney cancer
At 1:20 pm, Shilpa Medicare was trading at 491.55, up nearly 4% on the BSE.From the beginning of the year, Shilpa Medicare gained 75% against a drop of 15% in the benchmark Sensex
SHILPA MEDICARE LTD. - 530549 - SHILPA MEDICARE LIMITED LAUNCHES FIRST AFFORDABLE GENERIC DRUG TO TREAT ADVANCED KIDNEY CANCER
In continuation to our recent Successful Launches of Three Products in the Cancer therapy, Lenvatinib 'LENSHIL(r)' Dasatinib 'DASASHIL(r)' and Ibrutinib 'IBRUSHIL(r)' in India Market, Shilpa Medicare Limited today launches the Indian branded generic of Axitinib, an tyrosine kinase inhibitor drug with a brand name AXISHIL. AXISHIL is available as 1 mg & 5 mg tablets in pack of 14's Tablets in one bottle. AXISHIL is used to treat patients suffering from Advanced Renal Cell Carcinoma (RCC). This novel targeted therapy attacks cancer cells without damaging normal cells, thus causing fewer side effects. There has been a significant improvement in survival rates in patients with advanced renal cancer due to advent of this novel targeted therapy. Currently the monthly therapy cost of innovator is approximately 1.66 Lacs and with the launch of AXISHIL, monthly cost of treatment will be reduced drastically to Rs. 14940/-. SHILPA MEDICARE LTD. - 530549 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of the SEBI (listing Obligations and Disclosure Requirements) Regulations, 2015, read with CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report of the Company for the financial year 2019-20 issued by M/s P.S. Rao & Associates, Practicing Company Secretaries. This is for your information and Records SHILPA MEDICARE LTD. - 530549 - Declaration Pursuant To Regulation 33(3) (D) Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For Unmodified Opinion
I Vishnukant C. Bhutada, Managing Director of Shilpa Medicare Limited (CIN: L85110KA1987PLC008739) having registered office at 12-6-214/A-1, Shilpa House, Hyderabad Road, Raichur - 584135, Karnataka, hereby declare that the Statutory Auditors of the Company M/s Brahmayya & Co. Chartered Accountants represented by its Partner Mr. K. Sharavan holding membership Number: 215798 have issued an audit report with unmodified opinion on audited financial results for the Quarter and Year Ended 31st March, 2020. The declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (LODR) Regulations, 2015 as amended vide its circular no CIR/CFD/CMD/56/2016 dated 27th May, 2016. SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time, please find herewith enclosed updated copy of 04th Quarter and Financial Year 2019-20 Results presentation made to analysts and Investors SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
04th Quarter and Financial Year 2019-20 Results presentation made to analysts and Investors.
Shilpa Medicare shares fall 9% despite strong a Q4 result
In addition, Shilpa Medicare said it decided to acquire FTF Pharma for Rs 75 crore. It will also acquire Auxilla Pharmaceuticals and Research LLP through its subsidiary Shilpa Corporate Holdings, it added. SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Meeting Updates
1.To acquire FTF Pharma Private Limited subject to the agreed terms and conditions . 2.To Acquire Auxilla Pharmaceuticals And Research LLP through Shilpa Corporate Holdings Private Limited a Wholly Subsidiary of the Company subject to the agreed terms and conditions. SHILPA MEDICARE LTD. - 530549 - Sub: Outcome Of Board Meeting Held On 15Th June, 2020. Ref: Regulation 30 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015; Scrip Code: BSE- 530549/ Stock Symbol: NSE - SHILPAMED
With reference to the captioned subject, please note that the Board of Directors of the Company, at its meeting held today, inter-alia, considered and approved the Audited Financial Results (Standalone and Consolidated) as per Indian Accounting Standards (Ind- AS) along with the Independent Auditor's Report thereon for the Quarter and Year ended 31st March, 2020. A copy of the said Audited Financial Results along with the Independent Auditor's Report thereon is enclosed herewith. The meeting commenced at 14:30 hours and concluded at 18:15 hours . This is for your information and necessary records. SHILPA MEDICARE LTD. - 530549 - Sub: Outcome Of Board Meeting Held On 15Th June, 2020. Ref: Regulation 30 Of The SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015; Scrip Code: BSE- 530549/ Stock Symbol: NSE - SHILPAMED
With reference to the captioned subject, please note that the Board of Directors of the Company, at its meeting held today, inter-alia, considered and approved the Audited Financial Results (Standalone and Consolidated) as per Indian Accounting Standards (Ind- AS) along with the Independent Auditor's Report thereon for the Quarter and Year ended 31st March, 2020. A copy of the said Audited Financial Results along with the Independent Auditor's Report thereon is enclosed herewith. The meeting commenced at 14:30 hours and concluded at 18:15 hours . This is for your information and necessary records.